# PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
Canonical URL: https://biopharmsignal.com/news/PRTC/puretech-to-showcase-deupirfenidone-program-at-the-american-thoracic-society-international-conference
Ticker: PRTC
Company: PureTech Health
Source: PureTech Health
Published: 2026-05-13 11:00 EST
Original Source URL: https://investors.puretechhealth.com
## Summary

RNS Number: 1044E PureTech Health PLC 13 May 2026   13 May 2026 PureTech Health plc   PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference   Presentations to highlight differentiated approach to advancing deupirfenidone, reinforcing its potential to

## Article Body
RNS Number: 1044E PureTech Health PLC 13 May 2026   13 May 2026 PureTech Health plc   PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference   Presentations to highlight differentiated approach to advancing deupirfenidone, reinforcing its potential to
## Recent Company News
- 2026-05-13 11:00 EST — [PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference](https://biopharmsignal.com/news/PRTC/puretech-to-showcase-deupirfenidone-program-at-the-american-thoracic-society-international-conference) — Source: PureTech Health
- 2026-05-01 06:00 EST — [PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering](https://biopharmsignal.com/news/PRTC/puretech-founded-entity-seaport-therapeutics-announces-pricing-of-upsized-initial-public-offering) — Source: PureTech Health
- 2026-04-29 06:01 EST — [PureTech Announces Annual Results for Year Ended December 31, 2025](https://biopharmsignal.com/news/PRTC/puretech-announces-annual-results-for-year-ended-december-31-2025) — Source: PureTech Health
- 2026-04-29 06:00 EST — [PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange](https://biopharmsignal.com/news/PRTC/puretech-announces-intention-to-voluntarily-delist-american-depositary-shares-from-nasdaq-and-concentrate-trading-on-the-london-stock-exchange) — Source: PureTech Health
- 2026-04-27 11:05 EST — [PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors](https://biopharmsignal.com/news/PRTC/puretech-founded-entity-seaport-therapeutics-adds-intra-cellular-therapies-founder-and-ceo-dr-sharon-mates-to-its-board-of-directors) — Source: PureTech Health
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)